Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7340242

N=C(N)c1ccc2cc(C#CCc3ccccc3)ccc2c1.O=C(O)C(F)(F)F

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ASIC3 Q9UHC3 1/20 0.59
PLAU P00749 12/20 0.53
F2 P00734 6/20 0.44
PLG P00747 4/20 0.44
KLK1 P06870 4/20 0.44
KLKB1 P03952 2/20 0.44
PRSS1 P07477 2/20 0.44
PLAT P00750 3/20 0.44
FFAR1 O14842 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
MMP13 P45452 1/20 0.42
F9 P00740 1/20 0.42
TMPRSS6 Q8IU80 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7336009 0.90 ASIC3 (0.55) ASIC3PLAUF2PLGKLK1
Trifluoroacetic Acid SCHEMBL7337623 0.88 ASIC3 (0.53) ASIC3PLAUF2PLGKLK1
Trifluoroacetic Acid SCHEMBL7335057 0.87 ASIC3 (0.79) ASIC3PLAUF2PLGKLK1
Trifluoroacetic Acid SCHEMBL7337810 0.83 ASIC3 (0.51) ASIC3PLAUF2PLGKLK1
Trifluoroacetic Acid SCHEMBL7353483 0.81 ASIC3 (0.64) ASIC3PLAUF2PLGKLK1
Trifluoroacetic Acid SCHEMBL7335751 0.81 PLAU (0.80) ASIC3PLAUF2PLGKLK1
Trifluoroacetic Acid SCHEMBL7342361 0.79 PLAU (0.79) PLAUF2PLGKLK1KLKB1
Trifluoroacetic Acid SCHEMBL7334279 0.78 ASIC3 (0.46) ASIC3PLAUF2PLGKLK1
Trifluoroacetic Acid SCHEMBL7336945 0.78 ASIC3 (0.46) ASIC3PLAUF2PLGKLK1
Trifluoroacetic Acid SCHEMBL7345645 0.75 PLAU (0.59) ASIC3PLAUF2PLGKLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 ASIC3 4314/4885PLAU 2/4885F2 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.